These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2248149)

  • 21. Partial dystrophin deficiency in monozygous twin carriers of the Duchenne gene discordant for clinical myopathy.
    Bonilla E; Younger DS; Chang HW; Tantravahi U; Miranda AF; Medori R; DiMauro S; Warburton D; Rowland LP
    Neurology; 1990 Aug; 40(8):1267-70. PubMed ID: 2199849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monozygotic female twin carriers discordant for the clinical manifestations of Duchenne muscular dystrophy.
    Chutkow JG; Hyser CL; Edwards JA; Heffner RR; Czyrny JJ
    Neurology; 1987 Jul; 37(7):1147-51. PubMed ID: 2885783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical aspects of myoblast implantation: investigations on two inherited myopathies in animals.
    Morgan JE
    Adv Exp Med Biol; 1990; 280():89-94; discussion 95-6. PubMed ID: 2248159
    [No Abstract]   [Full Text] [Related]  

  • 24. Genetic counseling of isolated carriers of Duchenne muscular dystrophy.
    Hoffman EP; Pegoraro E; Scacheri P; Burns RG; Taber JW; Weiss L; Spiro A; Blattner P
    Am J Med Genet; 1996 Jun; 63(4):573-80. PubMed ID: 8826437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invited review: myoblast transfer: a possible therapy for inherited myopathies?
    Partridge TA
    Muscle Nerve; 1991 Mar; 14(3):197-212. PubMed ID: 2041542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical consequences of X-chromosome inactivation: Duchenne muscular dystrophy in one of monozygotic twins.
    Pena SD; Karpati G; Carpenter S; Fraser FC
    J Neurol Sci; 1987 Jul; 79(3):337-44. PubMed ID: 3612177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of quantitative myometry in the evaluation of myoblast transfer therapy.
    Munsat TL
    Adv Exp Med Biol; 1990; 280():227-9. PubMed ID: 2248142
    [No Abstract]   [Full Text] [Related]  

  • 28. Purification and proliferation of human myoblasts isolated with fluorescence activated cell sorting.
    Blau HM; Webster C; Pavlath GK
    Adv Exp Med Biol; 1990; 280():97-100. PubMed ID: 2248160
    [No Abstract]   [Full Text] [Related]  

  • 29. Myoblast transfer in DMD: problems in the interpretation of efficiency.
    Karpati G; Holland P; Worton RG
    Muscle Nerve; 1992 Oct; 15(10):1209-10. PubMed ID: 1406777
    [No Abstract]   [Full Text] [Related]  

  • 30. Dystrophin negative skeletal and myocardial muscle cells in a carrier of Duchenne's muscular dystrophy.
    Watanabe K; Izumi T; Natsui M; Matsubara N; Miyakita Y; Koyama S; Inomata T; Suzuki M; Shibata A
    Eur Heart J; 1993 Jul; 14(7):989-92. PubMed ID: 8375425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myoblast transplantation.
    Law PK
    Science; 1992 Sep; 257(5075):1329; author reply 1329-30. PubMed ID: 1529326
    [No Abstract]   [Full Text] [Related]  

  • 32. Quantitation of muscle mass and muscle protein synthesis rate: documenting a response to myoblast transfer.
    Griggs RC
    Adv Exp Med Biol; 1990; 280():235-40. PubMed ID: 2248144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Monozygotic twins with progressive muscular dystrophy].
    Radu H; Killyen I; Rosu AM; Ionescu V
    Z Neurol; 1972; 202(3):241-6. PubMed ID: 4120053
    [No Abstract]   [Full Text] [Related]  

  • 34. Integrated dystrophin analysis using immunocytochemical, biochemical and genetic techniques.
    Nicholson LV; Johnson MA; Davies KE
    Basic Appl Histochem; 1990; 34(3):169-75. PubMed ID: 1702616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive therapy in Duchenne muscular dystrophy: considerations for myoblast transfer studies.
    Mendell JR
    Adv Exp Med Biol; 1990; 280():287-95. PubMed ID: 2248150
    [No Abstract]   [Full Text] [Related]  

  • 36. [DNA and dystrophin analysis in Duchenne's and Becker's disease; benefit to the patient].
    Jennekens FG; Ippel PF
    Ned Tijdschr Geneeskd; 1993 Jan; 137(2):61-3. PubMed ID: 8421528
    [No Abstract]   [Full Text] [Related]  

  • 37. Cell and gene therapy in Duchenne muscular dystrophy.
    Morgan JE
    Hum Gene Ther; 1994 Feb; 5(2):165-73. PubMed ID: 7514447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunostaining of dystrophin and utrophin in skeletal muscle of dystrophinopathies.
    Sahashi K; Ibi T; Suoh H; Nakao N; Tashiro M; Marui K; Arahata K; Sugita H
    Intern Med; 1994 May; 33(5):277-83. PubMed ID: 7949630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On dystrophin abundance and C-terminal missense mutations in dystrophinopathies.
    Oexle K; Heyer R
    Ann Neurol; 1999 Jul; 46(1):137-8. PubMed ID: 10401797
    [No Abstract]   [Full Text] [Related]  

  • 40. Normal and dystrophin-deficient muscle fibers in carriers of the gene for Duchenne muscular dystrophy.
    Bonilla E; Schmidt B; Samitt CE; Miranda AF; Hays AP; de Oliveira AB; Chang HW; Servidei S; Ricci E; Younger DS
    Am J Pathol; 1988 Dec; 133(3):440-5. PubMed ID: 3059802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.